Well, it will obviously depend on the results of the trial.
I wish we had seen some MITIGATE results already.
I think Vascepa is more of a long-Covid play. I say this because I'm not sure of its efficacy for acute treatment. Most trials have shown greatest efficacy in the 2+ year range. Granted, that is for CVD, but I don't know if the pathways are similar.
Market Data 
Markets 
AI
